Differential diagnosis of Creutzfeldt–Jakob disease (CJD) versus other—sometimes treatable—neurological disorders is challenging, owing in part to uncertainty about the utility of recommended diagnostic tools. Two recent studies have addressed the reliability of cerebrospinal fluid biomarkers in identification of patients with sporadic CJD among clinically suspected cases.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Sensitive protein misfolding cyclic amplification of sporadic Creutzfeldt–Jakob disease prions is strongly seed and substrate dependent
Scientific Reports Open Access 18 February 2021
-
Towards an improved early diagnosis of neurodegenerative diseases: the emerging role of in vitro conversion assays for protein amyloids
Acta Neuropathologica Communications Open Access 25 July 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hsich, G., Kenney, K., Gibbs, C. J., Lee, K. H. & Harrington, M. G. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N. Engl. J. Med. 335, 924–930 (1996).
Zerr, I. et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease. Neurology 55, 811–815 (2000).
Zerr, I. et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt–Jakob disease. Brain 132, 2659–2668 (2009).
Geschwind, M. D. et al. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt–Jakob disease. Arch. Neurol. 60, 813–816 (2003).
Muayqil, T., Gronseth, G. & Camicioli, R. Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt–Jakob disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 79, 1499–1506 (2012).
Stoeck, K. et al. Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt–Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain 135, 3051–3061 (2012).
Chitravas, N. et al. Treatable neurological disorders misdiagnosed as Creutzfeldt–Jakob disease. Ann. Neurol. 70, 437–444 (2011).
Parchi, P., Strammiello, R., Giese, A. & Kretzschmar, H. Phenotypic variability of sporadic human prion disease and its molecular basis: past, present, and future. Acta Neuropathol. 121, 91–112 (2011).
Zou, W. Q. et al. Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann. Neurol. 68, 162–172 (2010).
Atarashi, R. et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat. Med. 17, 175–178 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Parchi, P., Capellari, S. Diagnostic value of cerebrospinal fluid markers. Nat Rev Neurol 9, 10–11 (2013). https://doi.org/10.1038/nrneurol.2012.253
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2012.253
This article is cited by
-
Sensitive protein misfolding cyclic amplification of sporadic Creutzfeldt–Jakob disease prions is strongly seed and substrate dependent
Scientific Reports (2021)
-
Towards an improved early diagnosis of neurodegenerative diseases: the emerging role of in vitro conversion assays for protein amyloids
Acta Neuropathologica Communications (2020)
